Hoth Therapeutics Inc Cash Flow Conversion Efficiency
Hoth Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Hoth Therapeutics Inc (HOTH) has a cash flow conversion efficiency ratio of -0.362x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.97 Million) by net assets ($8.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hoth Therapeutics Inc (2017–2025)
Cash flow conversion efficiency of Hoth Therapeutics Inc from 2017 to 2025. This chart illustrates how Hoth Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HOTH live share price for real-time trading data and today's change.
Hoth Therapeutics Inc Cash Flow Conversion Ratio Explained
Hoth Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hoth Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hoth Therapeutics Inc ranked by their cash flow conversion efficiency. Also see HOTH market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Menkul Degerler AS
IS:GLBMD
|
0.070x |
|
Immo Mcc NV
BR:MCC
|
N/A |
|
Tobii AB
ST:TOBII
|
0.063x |
|
Bong AB (publ)
ST:BONG
|
-0.007x |
|
Barnwell Industries Inc
NYSE MKT:BRN
|
-0.216x |
|
Thai Nondestructive Testing Public Company Limited
BK:TNDT
|
0.057x |
|
P3 Health Partners Inc
NASDAQ:PIII
|
-0.846x |
|
Lighting and Equipment Public Company Limited
BK:L&E
|
0.013x |
Annual Cash Flow Conversion Efficiency for Hoth Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hoth Therapeutics Inc from 2017 to 2025. Review Hoth Therapeutics Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.15 Million | $-9.80 Million | -1.594x | -57.12% |
| 2024-12-31 | $6.88 Million | $-6.98 Million | -1.014x | -14.55% |
| 2023-12-31 | $9.54 Million | $-8.45 Million | -0.886x | +51.22% |
| 2022-12-31 | $5.12 Million | $-9.30 Million | -1.815x | -48.39% |
| 2021-12-31 | $9.88 Million | $-12.09 Million | -1.223x | +7.33% |
| 2020-12-31 | $4.65 Million | $-6.13 Million | -1.320x | +36.06% |
| 2019-12-31 | $2.40 Million | $-4.95 Million | -2.065x | +84.78% |
| 2018-12-31 | $154.97K | $-2.10 Million | -13.568x | -3354.39% |
| 2017-12-31 | $1.18 Million | $-465.24K | -0.393x | -- |
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to … Read more